# This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component(Empagliflozin and Metformin) in Healthy Adult Volunteers in Fast Condition.

> **NCT05823870** · PHASE1 · COMPLETED · sponsor: **Dong Wha Pharmaceutical Co. Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** DW6014

## Key facts

- **NCT ID:** NCT05823870
- **Lead sponsor:** Dong Wha Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-24
- **Primary completion:** 2023-03-06
- **Final completion:** 2023-03-20
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05823870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05823870, "This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component(Empagliflozin and Metformin) in Healthy Adult Volunteers in Fast Condition.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05823870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*